Efficiency of Oseltamivir (Tamiflu) with Azithromycin Sustained Release (Zithromac SR) for inflammation

Efficiency of Oseltamivir (Tamiflu) with Azithromycin Sustained Release (Zithromac SR) for inflammation - Efficiency of Oseltamivir with AZM for influenza

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005371

Enrollment

100

Registered

2011-04-04

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Oseltamivir alone Oseltamivir plus Azithromycin Sustained Release

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who satisfied below 1-6: 1. Age:>=20 2. Agreement with documents 3. Fever>=38.0 degrees Celsius 4. >=2 items of ISS* which as moderate symptoms 5. Within 48hour after onset: Onset time is defined as below 1) First time at increase of body temperature (>= 1 degrees Celsius as usual) 2) First time which the patient aware >= 1 items of ISS* 6. Positive for Rapid Antigen Test kit *ISS=Influenza Symptoms Severity

Exclusion criteria

Exclusion criteria: 1. Hypersensitive with the examined drugs 2. Using contraindicated drugs with the examined drugs 3. Inappropriate judged by doctors Ex. Obvious bacterial superinfection 4. Using long and low dose Macrolides

Design outcomes

Primary

Measure	Time frame
Inhibitory effects of inflammatory cytokines/chemokines, including HMGB-1 and PCT in sera of the patients	—

Secondary

Measure	Time frame
Fever, Symptoms, Complications, and Adverse effects	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026